$PLSE
PULSE BIOSCIENCES, INC. Stock $plse

$plse Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000143774924015092 Filed on May 07, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.496M	$3.874M
YoY Change	27.37%	3.78%
% of Gross Profit
Research & Development	$7.230M	$6.741M
YoY Change	7.96%	15.65%
% of Gross Profit
Depreciation & Amortization	$100.0K	$100.0K
YoY Change	0.0%	0.0%
% of Gross Profit
Operating Expenses	$7.230M	$6.741M
YoY Change	7.96%	15.65%
Operating Profit	-$11.73M	-$10.62M
YoY Change	14.66%	11.01%
Interest Expense	$343.0K	$478.0K
YoY Change	8.2%	-300.0%
% of Operating Profit
Other Income/Expense, Net	$343.0K	$478.0K
YoY Change	8.2%	-300.0%
Pretax Income	-$11.38M	-$10.14M
YoY Change	14.86%	3.43%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$11.38M	-$10.10M
YoY Change	14.86%	3.05%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.20	-$0.18
Diluted Earnings Per Share	-$0.20	-$0.18
COMMON SHARES
Basic Shares Outstanding	55.23M	55.23M
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$26.20M	$34.89M
YoY Change	-55.41%	-35.52%
Cash & Equivalents	$26.20M	$34.90M
Short-Term Investments
Other Short-Term Assets	$1.043M	$964.0K
YoY Change	-13.87%	13.55%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$27.24M	$35.85M
YoY Change	-54.57%	-34.76%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.313M	$1.400M
YoY Change	-25.19%	-24.93%
Goodwill	$2.791M	$2.791M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$714.0K	$365.0K
YoY Change	95.62%	0.0%
Total Long-Term Assets	$13.19M	$13.32M
YoY Change	-10.88%	-12.83%
TOTAL ASSETS
Total Short-Term Assets	$27.24M	$35.85M
Total Long-Term Assets	$13.19M	$13.32M
Total Assets	$40.43M	$49.16M
YoY Change	-45.92%	-29.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.637M	$1.712M
YoY Change	-8.75%	-20.74%
Accrued Expenses	$3.179M	$2.268M
YoY Change	11.78%	-26.63%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.962M	$5.081M
YoY Change	6.22%	-27.32%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$7.497M	$7.796M
YoY Change	-13.27%	-12.38%
Total Long-Term Liabilities	$7.497M	$7.796M
YoY Change	-13.27%	-89.45%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.962M	$5.081M
Total Long-Term Liabilities	$7.497M	$7.796M
Total Liabilities	$13.46M	$12.88M
YoY Change	-5.6%	-84.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$358.4M	-$347.1M
YoY Change	14.0%	13.99%
Common Stock	$385.4M	$383.3M
YoY Change	2.8%	30.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$26.97M	$36.29M
YoY Change
Total Liabilities & Shareholders Equity	$40.43M	$49.16M
YoY Change	-45.92%	-29.99%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$11.38M	-$10.10M
YoY Change	14.86%	3.05%
Depreciation, Depletion And Amortization	$100.0K	$100.0K
YoY Change	0.0%	0.0%
Cash From Operating Activities	-$8.395M	-$9.800M
YoY Change	-8.77%	49.16%
INVESTING ACTIVITIES
Capital Expenditures	$29.00K	$5.000K
YoY Change	81.25%	-87.18%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$29.00K	-$5.000K
YoY Change	81.25%	-87.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-265.0K	$305.0K
YoY Change	-101.91%	-170.6%
NET CHANGE
Cash From Operating Activities	-8.395M	-$9.800M
Cash From Investing Activities	-29.00K	-$5.000K
Cash From Financing Activities	-265.0K	$305.0K
Net Change In Cash	-8.689M	-$9.480M
YoY Change	-286.9%	34.64%
FREE CASH FLOW
Cash From Operating Activities	-$8.395M	-$9.800M
Capital Expenditures	$29.00K	$5.000K
Free Cash Flow	-$8.424M	-$9.805M
YoY Change	-8.61%	48.36%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55225000
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55225000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55144000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55144000
CY2023	plse	Impairment Of Marketable Securities ImpairmentOfMarketableSecurities	0	usd
CY2024Q1	plse	Impairment Of Marketable Securities ImpairmentOfMarketableSecurities	0	usd
CY2023Q1	us-gaap	Depreciation Depreciation	100000	usd
CY2024Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q1	us-gaap	Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2024#CostsAndExpenses
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-34899
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-5696597
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	3957 Point Eden Way
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Hayward
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94545
CY2024Q1	dei	City Area Code CityAreaCode	510
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	906-4600
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2024Q1	dei	Trading Symbol TradingSymbol	PLSE
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	55225333
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34885000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44365000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	964000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	963000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	35849000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	45328000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1400000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1528000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1719000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1886000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	2791000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	2791000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7040000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7256000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	365000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	365000	usd
CY2024Q1	us-gaap	Assets Assets	49164000	usd
CY2023Q4	us-gaap	Assets Assets	59154000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1712000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1836000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2268000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3814000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1101000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1058000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5081000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6708000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7796000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8086000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	12877000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	14794000	usd
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	55000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	55000	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	383284000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	381220000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-347052000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-336915000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	36287000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	44360000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	49164000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	59154000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6741000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5829000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3874000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3733000	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	10615000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	9562000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-10615000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9562000	usd
CY2024Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	478000	usd
CY2023Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-239000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	478000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-239000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10137000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9801000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-10137000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-9801000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10137000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9801000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55172000
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37390000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-10137000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-9801000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	132000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	135000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	167000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	167000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1759000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	896000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-7000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-160000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	7000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	1000	usd
CY2024Q1	plse	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-216000	usd
CY2023Q1	plse	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-193000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-124000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	587000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1546000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	496000	usd
CY2024Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	4000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-247000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-207000	usd
CY2024Q1	us-gaap	Increase Decrease In Notes Payable Related Parties IncreaseDecreaseInNotesPayableRelatedParties	0	usd
CY2023Q1	us-gaap	Increase Decrease In Notes Payable Related Parties IncreaseDecreaseInNotesPayableRelatedParties	801000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9780000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6570000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	39000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-39000	usd
CY2024Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	296000	usd
CY2023Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	291000	usd
CY2024Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2023Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	194000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2024Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	-0	usd
CY2023Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	917000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	305000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-432000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9480000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7041000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	44365000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	61139000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	34885000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	54098000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	44360000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	296000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1759000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-10137000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	36287000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2248000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	291000	usd
CY2023Q1	plse	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	194000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	896000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-9801000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-10668000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-347100000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9800000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34900000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-10100000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates that affect the amounts reported in the financial statements and accompanying notes to the financial statements. Estimates include, but are <i><em style="font: inherit;">not</em></i> limited to, the valuation and recognition of stock-based compensation, inventory valuation, warranty obligations, income taxes, and the useful lives assigned to long-lived assets. The Company evaluates its estimates and assumptions based on historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ materially from these estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
CY2023Q4	us-gaap	Standard Product Warranty Accrual Current StandardProductWarrantyAccrualCurrent	0	usd
CY2022Q4	us-gaap	Standard Product Warranty Accrual Current StandardProductWarrantyAccrualCurrent	50000	usd
CY2024Q1	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	0	usd
CY2023Q1	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	0	usd
CY2024Q1	plse	Adjustment For Inventory At Cost AdjustmentForInventoryAtCost	0	usd
CY2023Q1	plse	Adjustment For Inventory At Cost AdjustmentForInventoryAtCost	0	usd
CY2024Q1	us-gaap	Standard Product Warranty Accrual Current StandardProductWarrantyAccrualCurrent	0	usd
CY2023Q1	us-gaap	Standard Product Warranty Accrual Current StandardProductWarrantyAccrualCurrent	50000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3476000	usd
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10096411
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12816403
CY2024Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	32702000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	41184000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5009000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5004000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3609000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1400000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1528000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	100000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P12Y
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6266000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6099000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1719000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1886000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	498000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	665000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	556000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1719000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1783000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3199000	usd
CY2024Q1	plse	Accrued Clinical Trial Fees And Costs AccruedClinicalTrialFeesAndCosts	56000	usd
CY2023Q4	plse	Accrued Clinical Trial Fees And Costs AccruedClinicalTrialFeesAndCosts	84000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	232000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	343000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	197000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	188000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2268000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3814000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1759000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	896000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1759000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	896000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7040000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7256000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1101000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1058000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7796000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8086000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	8897000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	9144000	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	469000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	453000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1441000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1977000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2046000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2117000	usd
CY2024Q1	plse	Lessee Operating Lease Liability To Be Paid After Year Three LesseeOperatingLeaseLiabilityToBePaidAfterYearThree	4074000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	11655000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2758000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	8897000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y7M2D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10	pure
CY2024Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	600000	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	500000	usd
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	pure

Files In Submission

Name	View Source	Status
plse-20240331_def.xml	Edgar Link	unprocessable
0001437749-24-015092-index-headers.html	Edgar Link	pending
0001437749-24-015092-index.html	Edgar Link	pending
0001437749-24-015092.txt	Edgar Link	pending
0001437749-24-015092-xbrl.zip	Edgar Link	pending
ex_642897.htm	Edgar Link	pending
ex_642898.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
plse-20240331.xsd	Edgar Link	pending
plse20240331_10q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
plse-20240331_cal.xml	Edgar Link	unprocessable
plse-20240331_lab.xml	Edgar Link	unprocessable
plse-20240331_pre.xml	Edgar Link	unprocessable
plse20240331_10q_htm.xml	Edgar Link	completed
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PLSE
PULSE BIOSCIENCES, INC. Stock $plse

2024 Q2 Form 10-Q Financial Statement

#000143774924015092 Filed on May 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLSE PULSE BIOSCIENCES, INC. Stock $plse

2024 Q2 Form 10-Q Financial Statement

#000143774924015092 Filed on May 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLSE
PULSE BIOSCIENCES, INC. Stock $plse